{{Rsnum
|rsid=868
|Gene=TGFBR1
|Chromosome=9
|position=99149374
|Orientation=plus
|GMAF=0.1414
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=TGFBR1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 61.6 | 36.6 | 1.8
| HCB | 99.3 | 0.7 | 0.0
| JPT | 91.0 | 9.0 | 0.0
| YRI | 75.9 | 24.1 | 0.0
| ASW | 61.4 | 38.6 | 0.0
| CHB | 99.3 | 0.7 | 0.0
| CHD | 99.1 | 0.9 | 0.0
| GIH | 79.2 | 19.8 | 1.0
| LWK | 63.6 | 30.9 | 5.5
| MEX | 72.4 | 25.9 | 1.7
| MKK | 63.9 | 31.6 | 4.5
| TSI | 63.7 | 34.3 | 2.0
| HapMapRevision=28
}}[[rs868]] is a SNP in the transforming growth factor, beta receptor I [[TGFBR1]] gene.

A total of 1,157 Spanish cases with urothelial cell carcinoma of the bladder and 1,157 matched controls were analyzed for TGFBR1 SNP associations, and among patients with muscle-invasive [[bladder cancer]] tumors, a significant association between [[rs868]] and disease-specific mortality was found, with an allele dosage effect (p-trend = 0.003).
{{PMID|19004027}}

{{PMID Auto
|PMID=19299629
|Title=Sequencing of TGF-beta pathway genes in familial cases of intracranial aneurysm.
|OA=1
}}

{{PMID Auto
|PMID=19356949
|Title=Cytokine SNPs: Comparison of allele frequencies by race and implications for future studies.
|OA=1
}}

{{PMID Auto
|PMID=19509225
|Title=Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}